Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis

Zhao, Han; Xing, Chuan; Zhang, Jiaqi; He, Bing

doi:10.1186/s12978-021-01207-7

Reproductive Health

Table 1 Characteristics of studies included in the network meta-analysis

From: Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis

Study	Year	Region	Drugs				Size	F-up (wks)	Efficacy
Ahmad [13]	2008	India	Met vs TZDs	Met	850 mg	bid	31	24 w	FPG, FINS, HOMA-IR, BMI, WHR, TT, AND, mF-G score, Menstrual frequency, Adverse events
Ahmad [13]	2008	India		Rosi	2 mg	bid	30	24 w
Mohiyididden [14]	2013	UK		Met	500 mg	bid	17	12 w	FPG, FINS, TC, TG, HDL, LDL, BMI, TT, SHBG, Menstrual frequency, Adverse events
Mohiyididden [14]	2013	UK		Rosi	4 mg	qd	18	12 w
Yilmaz [15]	2005	Turkey		Met	850 mg	bid	25	12 w	BMI, WHR, AND, HOMA-IR, TC, TG, LDL, HDL, Menstrual frequency, Adverse events
Yilmaz [15]	2005	Turkey		Rosi	4 mg	qd	25	12 w
Sangeeta [16]	2012	India		Met	500 mg	bid	50	24 w	FINS, HOMA-IR, TC, HDL, mF-G score, TT, SHBG, Menstrual frequency, Adverse events
Sangeeta [16]	2012	India		Pio	15 mg	qd	50	24 w
Naka [17]	2011	Greece		Met	850 mg	bid	15	24 w	FPG, FINS, TC, TG, HDL, LDL, mF-G score, TT, SHBG, BMI, WHR, Adverse events
Naka [17]	2011	Greece		Pio	30 mg	qd	14	24 w
Jensterl [18]	2008	Slovenia		Met	850 mg	bid	15	24 w	FPG, FINS, HOMA-IR, TC, TG, HDL, LDL, BMI, TT, AND, Menstrual frequency, Adverse events
Jensterl [18]	2008	Slovenia		Rosi	4 mg	qd	11	24 w
Ortega [19]	2005	Mexico		Met	850 mg	tid	18	24 w	FPG, FINS, HOMA-IR, TC, TG, HDL, LDL, BMI, WHR, mF-G score, AND, Adverse events
Ortega [19]	2005	Mexico		Pio	30 mg	qd	17	24 w
Zeng [20]	2020	China	Met vs Met + TZDs	Met	500 mg	tid	44	12 w	FPG, FINS, HOMA-IR, TC, TG, HDL, LDL, BMI, TT, Adverse events
Zeng [20]	2020	China		Met + Pio	500 mg + 15 mg	bid	44	12 w
Wang X [21]	2014	China		Met	1000 mg	tid	43	24 w	FPG, FINS, HOMA-IR, HDL, LDL, BMI, WHR, TT, SHBG, mF-G score, Menstrual frequency, Adverse events
Wang X [21]	2014	China		Met + Pio	1000 mg + 5 mg	tid	43	24 w
Liang [22]	2019	China	Met vs TZDs vs Met + TZDs	Met	500 mg	tid	22	12 w	FPG, FINS, HOMA-IR, HDL, LDL, TC, TG, BMI, WHR, TT, Menstrual frequency
				Pio	30 mg	tid	21
				Met + Pio	500 mg + 30 mg	tid	23
Sohrevardi [23]	2016	Iran		Met	500 mg	tid	22	12 w	PFG, FINS, HOMA-IR, TC, TG, HDL, LDL, BMI, TT, WHR, Menstrual frequency, Adverse events
				Pio	30 mg	qd	21
				Met + Pio	500 mg + 30 mg	tid/qd	23
Jamilian [24]	2017	Iran	Met vs MI	Met	500 mg	tid	30	12 w	BMI, SHBG, TT, mF-G score
Jamilian [24]	2017	Iran		MI	2 g	bid	30	12 w	BMI, SHBG, TT, mF-G score
Shokrpour [25]	2019	Iran		Met	500 mg	tid	27	12 w	FPG, FINS, HOMA-IR, BMI, TC, TG, HDL-C, LDL-C
Shokrpour [25]	2019	Iran		MI	2 g	bid	26	12 w	FPG, FINS, HOMA-IR, BMI, TC, TG, HDL-C, LDL-C
Fruzzetti [26]	2016	Italy		Met	500 mg	tid	22	24 w	HOMA-IR, BMI, mF-G score, Menstrual frequency, Adverse events
Fruzzetti [26]	2016	Italy		MI	4 g	qd	24	24 w
Nehra [27]	2017	India		Met	500 mg	tid	30	12–24 w	FPG, FINS, HOMA-IR, TC, TG, HDL, LDL, TT, BMI, WHR
Nehra [27]	2017	India		MI	1 g	bid	30	12–24 w	FPG, FINS, HOMA-IR, TC, TG, HDL, LDL, TT, BMI, WHR
Du [28]	2018	China	Met vs MI + DCI	Met	500 mg	bid	32	24 w	FPG, FINS, HOMA-IR, TC, TG, HDL, LDL, AND, TT, SHBG, Menstrual frequency, Adverse events
Du [28]	2018	China	Met vs MI + DCI	MI + DCI	550 mg + 13.8 mg	bid	32	24 w
Pizzo [29]	2014	Italy	MI vs DCI	MI	4 g	qd	25	24 w	HOMA-IR, BMI, mF-G score, TT, AND, SHGB, Menstrual frequency
Pizzo [29]	2014	Italy	MI vs DCI	DCI	1 g	qd	25	24 w
Donne [30]	2019	Italy	MI vs MI + DCI	MI	4 g	qd	10	12–24 w	mF-G score, WHR, BMI, Menstrual frequency
Donne [30]	2019	Italy		MI + DCI	1.1 g + 27.6 mg	qd	12	12–24 w	mF-G score, WHR, BMI, Menstrual frequency
Nordio [31]	2012	Italy		MI	2 g	bid	24	12–24 w	BMI, WHR, FPG, FINS, HOMA-IR, TT, SHBG, AND, Menstrual frequency
Nordio [31]	2012	Italy		MI + DCI	550 mg + 13.8 mg	bid	26	12–24 w
Li [32]	2017	China	Met vs BBR	Met	500 mg	bid	29	12 w	FPG, FINS, HOMA-IR, TC, TG, HDL, LDL, BMI, TT, Adverse events
Li [32]	2017	China	Met vs BBR	BBR	300 mg	tid	26	12 w
Wang P [33]	2016	China	Met vs Met + BBR	Met	500 mg	tid	42	12 w	HOMA-IR, BMI, WHR
Wang P [33]	2016	China		Met + BBR	500 mg + 500 mg	tid	42	12 w	HOMA-IR, BMI, WHR
Wang L [34]	2011	China		Met	500 mg	tid	28	12 w	FPG, FINS, HOMA-IR, BMI, TT
Wang L [34]	2011	China		Met + BBR	500 mg + 500 mg	tid	28	12 w	FPG, FINS, HOMA-IR, BMI, TT

Met Metformin, TZDs thiazolidinediones, Rosi rosiglitazone, Pio pioglitazone, MI myo-inositol, DCI d-chiro-inositol, BBR berberine, TT total testosterone, SHBG sex hormone binding globulin, AND androstenedione, mF-G score modified Ferriman–Gallwey score, BMI body mass index, WHR waist–hip ratio, FPG fasting plasma glucose, FINS fasting insulin, HOMA-IR Homeostatic Model Assessment of Insulin Resistance, TG triglyceride, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol

Back to article page

ISSN: 1742-4755

Contact us

General enquiries: journalsubmissions@springernature.com